Employés de l'hôpital

A team of renowned experts and key opinion leaders from around the world

EXECUTIVE TEAM

IgnacioFaus_Strat%26BD_edited.jpg

Ignacio Faus, Ph.D., MBA

Chief Executive Officer,
Board member

Ph.D. Biochemistry Indiana University Bloomington, MBA Finance Kellogg School of Management, IESE Business School Executive Education Program. 27 years of experience in large and mid-size pharmaceutical companies, private and public biotech companies: Bristol Myers Squibb-INSERM-CNRS, Grupo Uriach, Ferrer, co-founder and CEO Palau Pharma (sold in 2013), CEO of listed company Mologen AG (MGN). Board member of several private biotechnology companies as well as Private Equity funds in Europe.

BrunoLafont_ManagingDirector_edited_edit

Bruno Lafont, M.Sc., Executive MBA

Co-founder & Deputy Managing Director,
Board member

Engineer in Biochemistry, National Institute of Applied Sciences (INSA), Toulouse. Excecutive MBA from EPFL Lausanne, Technology Management. 
Co-founder of NFL Biosciences in 2006, in charge of its management and of the pharmaceutical development of NFL 101 since 2009. Twelve years in the management team of PCM, an international French industrial group for which he launched and led the US subsidiary.

BOARD MEMBERS

Joël Besse, M.Sc., M.Sc.

President of the Board of Directors

Aerospace Engineer of ISAE Sup'aero and Master's degree from University of Toulouse. 

For 30 years venture capitalist (SED Ventures, Atlas Venture), Business Angel (Momentum Biotech), director (Actelion, Novexel, Novuspharma...), founder and consultant of biotech companies, medtech, foodtech and international venture capital funds.

Yannick Plétan, M.D.

Board member
Clinical Development expertise

Graduated in pneumology, immunology, clinical pharmacology and pharmacokinetics - postdoctoral fellow at INSERM and visiting professor at the University of California Davis. After starting his carreer in hospital practice, Yannick joined the pharmaceutical industry where he held management positions for 20 years in research and development and medical affairs: Sanofi, Pierre Fabre Research Institute, Pfizer and Roche-Genentech. Decisive role in the creation and global development of the nicotine patch, and in the final phase of development and the launch of Chantix®. Harvard Business School, Ecole des Hautes Etudes Commerciales (HEC).

FrancisAhner_edited.jpg

Francis Ahner, M.Sc., Patent Attorney

Board member
Intellectual Property expertise

Former President of the International Federation of Industrial Property Attorneys (IFIPA). M.Sc. Cheminal Engineering Ecole Nationale Supérieure de Chimie, graduate of the Center for International Industelectual Property Studies (CIIPS) and former professor at CIIPS. Industrial property consultant, specializing in chemistry, pharmacy and cosmetology, former partner of Regimbeau in Paris, where he spent 45 years. He is also a European agent with the European Patent Office (EPO), responsible for opposition and appeals for private companies and public bodies in France, the United States and Japan.

Michel Huc, Pharm.D.

Board member
Manufacturing and Regulatory Affairs expertise

Ph.D. in pharmacy, 30 years of expercience in the pharmaceutical industry. Previously managing director and chief pharmacist of several pharmaceutical companies.16 years with Pierre Fabre Laboratories with expertise in the development, manufacturing, quality control and regulatory affairs of botanical medicines where he was the pharmacist responsible for Pierre Fabre's herbal portfolio.

SCIENTIFIC ADVISORS

Prof. Carole Clair

Dr. Clair is the current President of the Society for Research on Nicotine and Tobacco Europe (SRNT-E). Graduate physician from the University of Lausanne (2002), FMH specialist in general internal medicine (2007), PhD thesis (MD) on the link between smoking and diabetes (2008). After clinical training, completed a postdoctoral fellowship (2009-2011) at the Center for General Internal Medicine and Tobaccoology at Massachusetts General Hospital (Boston), training in clinical epidemiology (Harvard School of Public Health - Boston). Master of Science degree (2012). In Switzerland, obtaining an FNS Ambizione grant (2015) to continue his research (stopping smoking in people with diabetes). Obtaining a Privat Docent and a CLINICAL title MER (2016), appointment as an assistant professor at the PMU (director of the research and development centre).

Prof. Paul Aveyard

Professor of Behavioural Medicine (Oxford), member of Wolfson College and Collaboration for Leadership in Applied Health Research and Care (Oxford). His job is to help people change their behaviour (prevention or treatment of serious diseases), based in particular on stopping or reducing tobacco use. He has served as President of the UK Society of Behavioural Medicine, Director of the Association for the Study of Obesity and a fellow of the Society for Research on Nicotine and Tobacco. Editor for the journals: Addiction and Cochrane Tobacco Addiction Group. Member of NICE and advised the Ministry of Health on smoking and obesity.

Dr. Mitch Nides

Dr. Nides is the President of Los Angeles Clinical Trials, specializing in clinical research and the development of products and drugs to help smokers stop using burnt tobacco.

Dr. Nides has been the lead investigator in more than 60 smoking cessation trials testing nicotine and nicotine-free products, including patches, gums, lozenges, inhalers, Zyban and varenicline. From 1987 to 1999, Dr. Nides was a research researcher on smoking cessation in the Department of Lung and Critical Care at UCLA School of Medicine. Over the years, Dr. Nides has trained thousands of physicians, pharmacists, nurses and other health professionals on how to help their smokers quit.

t%C3%A9l%C3%A9chargementc_edited.jpg

Prof. Scott Leischow

Dr. Leischow is a past president of the Society for Research on Nicotine and Tobacco (SRNT) and founder and editor-in-chief of the journal Tobacco Regulatory Science. He joined Arizona State University in June 2017, and is Professor and Director of Clinical and Translational Sciences. Previously, he was at the Arizona Mayo Clinic from 2012 to 2017, where he led the Health Equity and Community Health Research Program (REACH) and co-led cancer prevention and control. He was previously Associate Director at the University of Arizona Cancer Control Center and was also Head of the Tobacco Control Research Division at the National Cancer Institute and Senior Advisor for Tobacco Policy in the Office of the Secretary of the U.S. Department of Health and Human Services. His research focuses on pharmacological and behavioural treatments for tobacco dependence, tobacco regulation and population health.

Prof. Stuart Ferguson

Associate Professor Ferguson is a health psychologist at the College of Health and Medicine School of Medicine at the University of Tasmania in Australia. He is primarily interested in health-related behaviour change (for example, quitting smoking, managing weight, etc.). His main research interest is to explore the process and factors of relapse, especially in cigarette smokers. He is also interested in the effectiveness of treatment and the factors that influence the likelihood of treatment use and adherence to treatment in attempts to stop treatment. To explore these topics, Professor Assoc Ferguson uses a wide range of research methodologies, ranging from laboratory techniques to sophisticated field surveillance in near real time.

François Brackman, M.D.

Graduated from medicine, clinical pharmacology and human pharmacokinetics. 

Over 35 years in the pharmaceutical industry, as Vice President (Global Development and Medical Affairs), VP of Medical and Regulatory Affairs, Head of Development Platform. 

Member of boards of directors, strategic research and develoment boards and postfolio management committees. (Servier, Sandoz/Novartis, Fournier, Pierre Fabre). Involved in regulatory interactions with national/international authorities (FDA, Health Canada, EMA, ANSM, MHRA, Koseisho) for international development programs and marketing authorizations.